The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease

Synapse

Volumn 64, Issue 3, 2010, Pages 241-250

  McNaught, Kevin St P ^a   Jnobaptiste, Ruth ^a   Jackson, Tehone ^a   Jengelley, Toni Ann ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Dopaminergic neurons; PA700 and PA28; Parkinson's disease; Substantia nigra pars compacta; Ubiquitin proteasome system

Indexed keywords

ENZYME ACTIVATOR; PROTEASOME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); UBIQUITIN CONJUGATING ENZYME; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOCYTOCHEMISTRY; LOCUS CERULEUS; MALE; MESENCEPHALON; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; NORADRENERGIC NERVE; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; SUBSTANTIA NIGRA;

ACETYLCYSTEINE; ANIMALS; BLOTTING, WESTERN; CANAVANINE; CELL SURVIVAL; CELLS, CULTURED; CYSTEINE PROTEINASE INHIBITORS; DOPAMINE; IMMUNOHISTOCHEMISTRY; LOCUS COERULEUS; MALE; NERVE DEGENERATION; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN FOLDING; RATS; RATS, SPRAGUE-DAWLEY; ROTENONE; SUBSTANTIA NIGRA; UBIQUITIN-ACTIVATING ENZYMES; UBIQUITIN-CONJUGATING ENZYMES; UNCOUPLING AGENTS;

EID: 73449098171     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20719     Document Type: Article

References (66)

1. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P Halliwell B. 1997. Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69:1196-1203.
2. Braak H, Tredici KD, Rub U, de Vos RA, Jansen Steur EN, Braak E. 2003. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211.
3. Bulteau AL, Lundberg KC, Humphries KM, Sadek HA, Szweda PA, Friguet B, Szweda LI. 1999. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem 276:30057-30063.
4. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364:1167-1169.
5. Ciechanover A, Brundin P. 2003. The ubiquitin proteasome system in neurodegenerative diseases. Sometimes the chicken, sometimes the egg. Neuron 40:427-446.
6. Damier P, Hirsch EC, Agid Y, Graybiel AM. 1999. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain 122:1437-1448.
7. Davies KJ. 1987. Protein damage and degradation by oxygen radicals. I. General aspects. J Biol Chem 262:9895-9901.
8. Davies KJ, Delsignore ME. 1987. Protein damage and degradation by oxygen radicals. III. Modification of secondary and tertiary structure. J Biol Chem 262:9908-9913.
9. Davies KJ, Delsignore ME, Lin SW. 1987. Protein damage and degradation by oxygen radicals. II. Modification of amino acids. J Biol Chem 262:9902-9907.
10. DeMartino GN, Slaughter CA. 1999. The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274:22123-22126.
11. Dexter DT, Holley AE, Flitter WD, Slater TF, Wells FR, Daniel SE, Lees AJ, Jenner P, Marsden CD. 1994. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study. Mov Disord 9:92-97.
12. Ding Q, Reinacker K, Dimayuga E, Nukala V, Drake J, Butterfield DA, Dunn JC, Martin S, Bruce-Keller AJ, Keller JN. 2003. Role of the proteasome in protein oxidation and neural viability following low-level oxidative stress. FEBS Lett 546:228-232.
13. El-Khodor BF, Kholodilov NG, Yarygina O, Burke RE. 2001. The expression of mRNAs for the proteasome complex is developmentally regulated in the rat mesencephalon. Brain Res Dev Brain Res 129:47-56.
14. Eytan E, Ganoth D, Armon T, Hershko A. 1989. ATP-dependent incorporation of 20S protease into the 26S complex that degrades proteins conjugated to ubiquitin. Proc Natl Acad Sci USA 86:7751-7755.
15. Farout L, Lamare M, Clavel S, Briand M, Briand Y. 2003. Differential expression of ubiquitin and proteasome-dependent pathway components in rat tissues. Comp Biochem Physiol B Biochem Mol Biol 134:297-305.
16. Floor E, Wetzel MG. 1998. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268-275.
17. Forno LS. 1996. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
18. Furukawa Y, Vigouroux S, Wong H, Guttman M, Rajput AH, Ang L, Briand M, Kish SJ, Briand Y. 2002. Brain proteasomal function in sporadic Parkinson's disease and related disorders. Ann Neurol 51:779-782.
19. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290:985-989.
20. Gibb WR, Lees AJ. 1988. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752.
21. Goldberg AL. 2007. Functions of the proteasome: From protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35:12-17.
22. Good PF, Hsu A, Werner P, Perl DP, Olanow CW. 1998. Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57:338-342.
23. Hattori N, Mizuno Y. 2004. Pathogenetic mechanisms of parkin in Parkinson's disease. Lancet 364:722-724.
24. Hendil KB, Hartmann-Petersen R, Tanaka K. 2002. 26S Proteasomes function as stable entities. J Mol Biol 315:627-636.
25. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y. 1997. Neuronal vulnerability in Parkinson's disease. J Neural Transm Suppl 50:79-88.
26. Hoglinger GU, Carrard G, Michel PP, Medja F, Lombes A, Ruberg M, Friguet B, Hirsch EC. 2003. Dysfunction of mitochondrial complex I and the proteasome: Interactions between two biochemical deficits in a cellular model of Parkinson's disease. J Neurochem 86:1297-1307.
27. Keller JN, Gee J, Ding Q. 2002. The proteasome in brain aging. Ageing Res Rev 1:279-293.
28. Kikuchi S, Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro K. 2003. Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res 964:228-236.
29. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608.
30. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18:106-108.
31. Lang AE, Lozano AM. 1998a. Parkinson's disease. Second of two parts. N Engl J Med 339:1130-1143.
32. Lang AE, Lozano AM. 1998b. Parkinson's disease. First of two parts. N Engl J Med 339:1044-1053.
33. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452.
34. Liu CW, Giasson BI, Lewis KA, Lee VM, Demartino GN, Thomas PJ. 2005. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: Implications for pathogenesis of Parkinson's disease. J Biol Chem 280:22670-22678.
35. McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. 2003. Altered proteasomal function in sporadic Parkinson's disease. Exp Neurol 179:38-45.
36. McNaught KS, Jenner P. 2001. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297:191-194.
37. McNaught KS, Olanow CW. 2003. Proteolytic stress: A unifying concept in the etiopathogenesis of familial and sporadic Parkinson's disease. Ann Neurol 53(3 Suppl 1):S73-S86.
38. McNaught KS, Shashidharan P, Perl DP, Jenner P, Olanow CW. 2002a. Aggresome-related biogenesis of Lewy bodies. Eur J Neurosci 16:2136-2148.
39. McNaught KSP, Mytilineou C, JnoBaptiste R, Jabut J, Shashidharan P, Jenner P, Olanow CW. 2002b. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301-306.
40. Meiners S, Heyken D, Weller A, Ludwig A, Stangl K, Kloetzel PM, Kruger E. 2003. Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes. J Biol Chem 278:21517-21525.
41. Mengual E, Arizti P, Rodrigo J, Gimenez-Amaya JM, Castano JG. 1996. Immunohistochemical distribution and electron microscopic subcellular localization of the proteasome in the rat CNS. J Neurosci 16:6331-6341.
42. Moore DJ, West AB, Dawson VL, Dawson TM. 2005. Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 25:55-84.
43. Mytilineou C, Kokotos Leonardi ET, Kramer BC, Jamindar T, Olanow CW. 1999. Glial cells mediate toxicity in glutathione-depleted mesencephalic cultures. J Neurochem 73:112-119.
44. Mytilineou C, McNaught KS, Shashidharan P, Yabut J, Baptiste RJ, Parnandi A, Olanow CW. 2004. Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress. J Neural Transm 111:1237-1251.
45. Mytilineou C, Walker RH, JnoBaptiste R, Olanow CW. 2003. Levodopa is toxic to dopamine neurons in an in vitro but not an in vivo model of oxidative stress. J Pharmacol Exp Ther 304:792-800.
46. Nair VD, McNaught KS, Gonzalez-Maeso J, Sealfon SC, Olanow CW. 2006. p53 Mediates non-transcriptional cell death in dopaminergic cells in response to proteasome inhibition. J Biol Chem 281:39550-39560.
47. Noda C, Tanahashi N, Shimbara N, Hendil KB, Tanaka K. 2000. Tissue distribution of constitutive proteasomes, immunoproteasomes, and PA28 in rats. Biochem Biophys Res Commun 277:348-354.
48. Pearce RK, Hawkes CH, Daniel SE. 1995. The anterior olfactory nucleus in Parkinson's disease. Mov Disord 10:283-287.
49. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, Choi P, Wolozin B, Farrer M, Hardy J, Cookson MR. 2002. Parkin protects against the toxicity associated with mutant alphasynuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007-1019.
50. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
51. Reaney SH, Johnston LC, Langston WJ, Di Monte DA. 2006. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol 202:434-440.
52. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, Grune T. 1998. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J 335:637-642.
53. Rideout HJ, Lang-Rollin ICJ, Savalle M, Stefanis L. 2005. Dopaminergic neurons in rat ventral midbrain cultures undergo selective apoptosis and form inclusions, but do not up-regulate iHSP, following proteasomal inhibition. J Neurochem 93:1304-1313.
54. Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. 1990. Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem 55:2142-2145.
55. Shamoto-Nagai M, Maruyama W, Kato Y, Isobe K, Tanaka M, Naoi M, Osawa T. 2003. An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74:589-597.
56. Shang F, Nowell TR Jr, Taylor A. 2001. Removal of oxidatively damaged proteins from lens cells by the ubiquitin-proteasome pathway. Exp Eye Res 73:229-238.
57. Shringarpure R, Grune T, Mehlhase J, Davies KJ. 2003. Ubiquitin conjugation is not required for the degradation of oxidized proteins by proteasome. J Biol Chem 278:311-318.
58. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD. 1994. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348-355.
59. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
60. Snyder H, Mensah K, Theisler C, Lee JM, Matouschek A, Wolozin B. 2003. Aggregated and monomeric alpha-synuclein bind to the S6′ proteasomal protein and inhibit proteasomal function. J Biol Chem 278:11753-11759.
61. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21:9549-9560.
62. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson VL, Dawson TM, Ross CA. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10:919-926.
63. Tofaris GK, Razzaq A, Ghetti B, Lilley K, Spillantini MG. 2003. Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J Biol Chem 278:44405-44411.
64. Tsirigotis M, Zhang M, Chiu RK, Wouters BG, Gray DA. 2001. Sensitivity of mammalian cells expressing mutant ubiquitin to protein damaging agents. J Biol Chem 276:46073-46078.
65. Voges D, Zwickl P, Baumeister W. 1999. The 26S proteasome: A molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015-1068.
66. Zarow C, Lyness SA, Mortimer JA, Chui HC. 2003. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol 60:337-341.